相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary *
Tze-Fan Chao et al.
THROMBOSIS AND HAEMOSTASIS (2022)
Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients
Giulio Francesco Romiti et al.
THROMBOSIS AND HAEMOSTASIS (2022)
Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study
Clara L. Rodriguez-Bernal et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Gerhard Hindricks et al.
EUROPEAN HEART JOURNAL (2021)
The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation
Tatjana S. Potpara et al.
THROMBOSIS AND HAEMOSTASIS (2021)
Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy
Gregory Y. H. Lip et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis
Madeleine Durand et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Real-World Comparative Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants vs. Warfarin in a Developing Country
Phatcharin Mitsuntisuk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation
Wayne A. Ray et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients
Danilo Menichelli et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting
Saima Afzal et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)
Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study
Sylvie Perreault et al.
PHARMACOTHERAPY (2021)
Statin treatment and outcomes after embolic stroke of undetermined source
Dimitrios Sagris et al.
INTERNAL AND EMERGENCY MEDICINE (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Pre-Stroke Statin Therapy Improves In-Hospital Prognosis Following Acute Ischemic Stroke Associated with Well-Controlled Nonvalvular Atrial Fibrillation
Pawel Wankowicz et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation
Krista F. Huybrechts et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation
M. Jansson et al.
THROMBOSIS RESEARCH (2020)
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
Ole-Christian W. Rutherford et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2020)
Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation
Lanting Yang et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation
[Anonymous]
ANNALS OF INTERNAL MEDICINE (2020)
Comparative Safety and Effectiveness of Direct-Acting Oral Anticoagulants Versus Warfarin: a National Cohort Study of Nursing Home Residents
Matthew Alcusky et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2020)
Comparative Effectiveness of Rivaroxaban, Apixaban, and Warfarin in Atrial Fibrillation Patients With Polypharmacy
Amgad Mentias et al.
STROKE (2020)
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation The NAXOS Study
Eric Van Ganse et al.
STROKE (2020)
Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin
Marie Bradley et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2020)
A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation-A Single-centre Retrospective Cohort Study in Singapore
Wen Jun Tiew et al.
ANNALS ACADEMY OF MEDICINE SINGAPORE (2020)
The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis
Oh Young Bang et al.
PLOS ONE (2020)
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population
Alpesh Amin et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2019)
Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure
Alpesh Amin et al.
PLOS ONE (2019)
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naive non-valvular atrial fibrillation patients in the US Department of defense population
Kiran Gupta et al.
BMC CARDIOVASCULAR DISORDERS (2019)
Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study
Sreeram Ramagopalan et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2019)
Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
Lars J. Kjerpeseth et al.
PLOS ONE (2019)
Effectiveness and Safety of Contemporary Oral Anticoagulants Among Asians With Nonvalvular Atrial Fibrillation
So-Ryoung Lee et al.
STROKE (2019)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation
David J. Graham et al.
AMERICAN JOURNAL OF MEDICINE (2019)
Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland
Tanja Mueller et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
Matthew A. Wanat et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2019)
Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
Todd C. Villines et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2019)
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
L. Staerk et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation A Systematic Review and Meta-Analysis
Marco Proietti et al.
STROKE (2018)
Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan
Alpesh Amin et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data
Shun Kohsaka et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice
Craig I. Coleman et al.
HEART LUNG AND CIRCULATION (2018)
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
Niklas W. Andersson et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation
Stefan H. Hohnloser et al.
THROMBOSIS AND HAEMOSTASIS (2018)
Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation
Sara Sjalander et al.
THROMBOSIS RESEARCH (2018)
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care
Yana Vinogradova et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care
Yana Vinogradova et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
Yi-Hsin Chan et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
Brandon K. Martinez et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases
Sreeram Ramagopalan et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2018)
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
Ping G. Tepper et al.
PLOS ONE (2018)
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients The ARISTOPHANES Study
Gregory Y. H. Lip et al.
STROKE (2018)
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study
Laila Staerk et al.
EUROPEAN HEART JOURNAL (2017)
Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study
Neena S. Abraham et al.
GASTROENTEROLOGY (2017)
Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making
Peter A. Noseworthy et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
The ABC pathway: an integrated approach to improve AF management
Gregory Y. H. Lip
NATURE REVIEWS CARDIOLOGY (2017)
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack
Craig I. Coleman et al.
STROKE (2017)
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in real-world clinical practice
Xiaoyan Li et al.
THROMBOSIS AND HAEMOSTASIS (2017)
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Peter Bronnum Nielsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Peter Bronnum Nielsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients
Morten Lamberts et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting
Jay Lin et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation
Gboyega Adeboyeje et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2017)
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor A Nationwide Cohort Study
Gregory Y. H. Lip et al.
JAMA CARDIOLOGY (2017)
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation
Inmaculada Hernandez et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study
Stefan H. Hohnloser et al.
CLINICAL RESEARCH IN CARDIOLOGY (2017)
Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data
Shun Kohsaka et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants
Sigrun Halvorsen et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2017)
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population
Alpesh Amin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients
Steven Deitelzweig et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on European patients
Antonio Gomez-Outes et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation
Peter A. Noseworthy et al.
CHEST (2016)
Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study
Craig I. Coleman et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic
Faris Al-Khalili et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants
Steve Deitelzweig et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a real-world observational study in the United States
Gregory Y. H. Lip et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Torben Bjerregaard Larsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
Torben Bjerregaard Larsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
Xiaoxi Yao et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
Sigrun Halvorsen et al.
EUROPEAN HEART JOURNAL (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
Safety and Efficacy of the Oral Direct Factor Xa Inhibitor Apixaban in Japanese Patients With Non-Valvular Atrial Fibrillation - The ARISTOTLE-J Study
Satoshi Ogawa et al.
CIRCULATION JOURNAL (2011)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
分享论文
